How do I read and understand my Breast Cancer pathology report

Understanding Your Breast Cancer Pathology Report

A pathology report is one of the most important documents you'll receive after a biopsy or surgery. It describes what the cancer cells look like under a microscope and provides critical information that guides your treatment plan. Let me walk you through what to expect and what the key findings mean.

What Is a Pathology Report?

Your pathology report is a detailed analysis of tissue samples taken from your breast. A pathologist (a doctor who specializes in examining tissue under a microscope) examines the cells and writes a report describing:

• What type of cancer you have
• How aggressive it appears (grade)
• Whether it has spread to lymph nodes
• Important biomarkers (protein markers) that determine treatment options

According to the NCCN Guidelines for Patients: Invasive Breast Cancer, understanding your test results is essential—the report forms the foundation for all treatment decisions.

---

Key Sections You'll Find in Your Report

1. DIAGNOSIS/CANCER TYPE

This section identifies what kind of breast cancer you have.

What to look for:

• Invasive Ductal Carcinoma (IDC) – Cancer that started in the milk ducts and has grown into surrounding breast tissue
• Invasive Lobular Carcinoma (ILC) – Cancer that started in the milk-producing glands (lobules) and has spread into surrounding tissue
• Other types – There are less common types like tubular, mucinous, or inflammatory breast cancer

Why it matters: The type helps your doctor predict how the cancer might behave and which treatments work best.

---

2. GRADE (Histologic Grade)

The grade describes how abnormal the cancer cells look compared to normal breast cells. It's scored on a scale of 1-3:

• Grade 1 (Low Grade/Well-Differentiated) – Cancer cells look fairly normal and organized. These tend to grow more slowly.
• Grade 2 (Intermediate Grade/Moderately Differentiated) – Cancer cells look somewhat abnormal. Growth is moderate.
• Grade 3 (High Grade/Poorly Differentiated) – Cancer cells look very abnormal and disorganized. These tend to grow faster and may be more aggressive.

Why it matters: Higher grades generally indicate more aggressive cancer, which may influence treatment intensity and urgency.

---

3. TUMOR SIZE (T Stage)

This describes the size of the main tumor.

What you'll see:

• Measurements in centimeters (cm)
• A "T" score (T0, T1, T2, T3, T4) that describes how large the tumor is and whether it has grown into nearby structures

According to the NCCN Guidelines, tumor size is one of three critical pieces of information (along with lymph node involvement and spread to distant sites) used to determine your cancer stage.

Why it matters: Larger tumors may require different treatment approaches than smaller ones.

---

4. LYMPH NODE STATUS (N Stage)

This tells you whether cancer has spread to nearby lymph nodes under your arm (axillary lymph nodes).

What to look for:

• N0 – No cancer in lymph nodes
• N1 – Cancer in 1-3 nearby lymph nodes
• N2 – Cancer in 4-9 nearby lymph nodes
• N3 – Cancer in 10 or more nearby lymph nodes

The report may also describe:

• How many lymph nodes were examined
• How many contained cancer
• Whether cancer is in the lymph node itself or just touching it

Why it matters: Lymph node involvement is a major factor in determining your stage and whether you need additional treatments like chemotherapy.

---

5. HORMONE RECEPTOR STATUS ⭐ CRITICAL

This is one of the most important findings because it directly determines which treatments will work for you.

Estrogen Receptor (ER):

• ER-Positive (ER+) – Cancer cells have receptors that respond to the hormone estrogen. These cancers can be treated with hormone-blocking therapies.
• ER-Negative (ER-) – Cancer cells don't have estrogen receptors, so hormone therapy won't work.

Progesterone Receptor (PR):

• PR-Positive (PR+) – Cancer cells respond to progesterone
• PR-Negative (PR-) – Cancer cells don't respond to progesterone

What you might see:

• Percentage of cells that are positive (e.g., "ER 95% positive")
• An intensity score (weak, moderate, or strong)

According to the NCCN Guidelines for Patients: Metastatic Breast Cancer, hormone receptor status is fundamental to treatment planning. The guidelines note that "treatment will be based on these findings. It is important you understand what these tests mean."

Why it matters:

• ER+/PR+ cancers typically respond well to endocrine (hormone) therapy, which may include tamoxifen, aromatase inhibitors, or other hormone-blocking drugs
• ER-/PR- cancers require different approaches, often chemotherapy or targeted therapy

---

6. HER2 STATUS ⭐ CRITICAL

HER2 (Human Epidermal Growth Factor Receptor 2) is a protein that can appear in high amounts on cancer cells.

What you'll see:

• HER2-Positive (HER2+) – Cancer cells have too much HER2 protein. These cancers respond to HER2-targeted therapies like trastuzumab (Herceptin) or pertuzumab (Perjeta).
• HER2-Negative (HER2-) – Cancer cells don't have excess HER2
• HER2-Equivocal – Results are unclear; additional testing (FISH or ISH) may be needed

Why it matters: HER2-positive cancers have specific targeted treatment options that can be very effective. The NCCN Guidelines emphasize that HER2 status is essential for determining your treatment plan.

---

7. MARGINS

This describes whether cancer cells were found at the edges of the tissue that was removed.

What to look for:

• Negative/Clear Margins – No cancer cells at the edges. This is what doctors want to see.
• Positive Margins – Cancer cells extend to the edge of the removed tissue, meaning some cancer may have been left behind
• Close Margins – Cancer cells are very near the edge (usually less than 2mm away)

Why it matters: Positive or close margins may mean you need additional surgery or radiation to remove remaining cancer cells.

---

8. LYMPHOVASCULAR INVASION (LVI)

This describes whether cancer cells were found inside blood vessels or lymph vessels in the breast tissue.

• Present – Cancer cells are in vessels
• Absent – No cancer cells in vessels

Why it matters: If present, it suggests cancer cells may have a pathway to spread, which can influence treatment decisions.

---

9. BIOMARKER TESTING ⭐ INCREASINGLY IMPORTANT

Beyond ER, PR, and HER2, your report may include testing for other biomarkers (genetic mutations or protein changes in the cancer cells).

According to the NCCN Guidelines for Patients: Metastatic Breast Cancer, certain mutations can be targeted with specific therapies:

Common biomarkers tested:

• PIK3CA mutations – Can be targeted with specific drugs
• ESR1 mutations – Found in hormone receptor-positive cancers; may indicate resistance to certain hormone therapies
• BRCA1/2 mutations – Inherited genetic changes that increase cancer risk and may affect treatment options
• PD-L1 status – Helps predict response to immunotherapy
• Tumor Mutational Burden (TMB) – The number of mutations in cancer cells; higher TMB may predict better response to immunotherapy

Why it matters: These findings can open up additional treatment options beyond standard chemotherapy or hormone therapy.

---

How to Organize This Information

The NCCN Guidelines recommend creating a medical binder to keep all your records organized:

✓ Make copies of your pathology report
✓ Create a folder for pathology and test results
✓ Organize items by date
✓ Use an online patient portal if available to download and store records
✓ Bring your binder to